ICOSA’s Post

The evolving landscape of biotechnology innovation As the second AI x Bio summit by DeciBio unfolds in NYC today, I'm struck by our field's journey from Rosalind Franklin's revolutionary Photo 51 (https://lnkd.in/eQqbqhAF) to the AI-powered future of biotechnology. Franklin's X-ray work in the 1950s cracked DNA's code (https://lnkd.in/eUHKEQaB). Now, we're witnessing another seismic shift: AI and biotech joining forces. I've been reviewing the recent white paper from the National Security Commission on Emerging Biotechnology (NSCEB). It paints a vivid picture of AI's game-changing role in biotech - from unraveling protein puzzles to fast-tracking pandemic responses. The NSCEB first interim report (https://lnkd.in/e6fDy3tq) key points: • AI is turbocharging biotech discoveries • We need to champion responsible AI innovation in biotech • We must harness AI x Bio's potential while navigating its risks Standing on the shoulders of trailblazers like Franklin, we're now using AI to push biotech's boundaries. The AI x Bio summit embodies this thrilling new frontier. As much as I can foresee many groundbreaking discoveries at the AI-biotech crossroads, I also realize that we must ensure these advances benefit everyone. Definitely something on my mind. What about you? Oh, and here's a fitting coincidence - today, July 25th, marks Rosalind Franklin's birthday. A perfect day to honor her legacy and look to the future she helped shape. #AIxBio #Biotech #Innovation #Future #TalkinBoutARevolution #RosalindFranklin #WomenInScience Illustration by EMxMJ

🚀 - 𝐁𝐢𝐨𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝟔 𝐧𝐞𝐰 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Bioptimus, the pioneering company building AI foundation models for biology, announced today that it has reached a 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐦𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐨𝐟 $𝟕𝟔 𝐦𝐢𝐥𝐥𝐢𝐨𝐧.   ▶ The funding will accelerate Bioptimus’ mission to build the world’s first multiscale and multimodal AI foundation model for biology, aimed at revolutionizing research and innovation across the pharma industry, biotech, and beyond.   The 𝗔𝗻𝗱𝗲𝗿𝗮 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 team is thrilled to welcome Bioptimus into the BioDiscovery portfolio and to be part of their inspiring journey!   To read the press release: https://lnkd.in/dZ-xbvaW   #AI #MedicalInnovation #LifeSciences cc Sofia Ioannidou, Mathieu Pieronne, Florian Gerard-Mercier, PhD

Attending BIO 2024? Then come visit our CEO and founder, Nikola Müller, at Germany Pavilion booth 4315 in San Diego from 3-6 June 2024. Knowing01 GmbH is a Munich-based start-up founded in 2020 with the mission to change the way life science data is used in research. Our goal is to help researchers in industry and academia get more out of their data, accelerate discoveries and create impact. Our easy-to-use software deeply connects biomedical datasets for robust insights and separates signal from noise. Would you like to learn more about knowing01's flexible software solution? Or how we can help you unlock the value of your data assets? Then now is your chance to meet our CEO and founder, Dr Nikola Müller, at Germany Pavilion booth 4315 at BIO International Convention 2024 in San Diego from 3-6 June 2024. Simply make a meeting request with knowing01 in the BIO partnering system: https://lnkd.in/ddSxCXMH Or contact us at: https://lnkd.in/edhAhvpZ #BIO2024 #knowing01 #StartUp #Biotechnology #Multiomics #Omics #DiseaseResearch #DataScience #DataAnalytics #AI #KnowledgeGraphs #Innovation #Research #WomenInIT #FemaleLeaders

The need for patient data governance is foundational for AI in drug discovery. Our thanks to BIA and Aline for a great panel. #personalisedhealthcare #precisionmedicine #axiamedicine

🔬 AI is transforming biotechnology and personalized medicine, and next week, our Co-Founder & CEO, Nabiha Saklayen, will be presenting next week at the "Big Data and AI in Biotech" event hosted by DANISH BIO - DANSK BIOTEK at Gorrissen Federspiel on October 2 in #Copenhagen. She’ll be sharing insights into the exciting applications of #AI in these fields. Joining her are Roald Forsberg of Raven biosciences and Martin S. Borchert of Novonesis, with Emma Jappe Lange of Biobridge Partners leading a roundtable on AI in the Nordics. 👉 See here for more details: https://lnkd.in/dfNSeAxR We're thrilled to participate in this important gathering! 🌐🤝 Martin Dræbye Gantzhorn, Morten Engsbye, Hans T. Schambye #Biotech #RegenMed #PersonalizedMedicine #ArtificialIntelligence #Biomanufacturing #RegenerativeMedicine #BigData #YourCellsYourCure #CellinoBio

Bioptimus, an AI company based in Paris, has raised $41M in its latest funding round, bringing its total funding to $76M. This comes less than a year after its initial seed round, signaling strong investor confidence. The funding, led by Cathay Innovation, will fuel Bioptimus’s mission to transform biological research with its groundbreaking AI model. Unlike traditional research that isolates different biological components, Bioptimus aims to break down these barriers. Their model integrates data from various biological scales—molecules, cells, tissues, and organisms—creating a holistic view of biology. CEO Jean-Philippe Vert likens their model to the "GPT of biology," except it simulates biology instead of generating text. This innovation promises to enhance research in fields like medicine, biotechnology, and even cosmetics, enabling more precise predictions of disease outcomes, responses to treatments, and drug designs. The company’s first major success, the H-Optimus-0 model for pathology, already outperforms others in independent benchmarks, including studies at Harvard and the University of Leeds. With the new funding, Bioptimus plans to further refine its platform, develop strategic partnerships, and expand its datasets, setting the stage for major breakthroughs in biological research and beyond. #Bioptimus #AIInnovation #GPTinBiology #FutureOfHealthcare #TechLeadership #BiotechRevolution #AIforMedicine #ResearchAdvancement #FundingSuccess #BiologyTransformation #dailysahar

💡 Insights from TechBio France 2024 💡 Yesterday’s event, hosted by AI for Health, France Biotech, France Deeptech, Future4Care, and WhiteLab Genomics, delivered key insights on the future landscape for #TechBio. Some highlights: 💼 Beyond science, “deal-making capacity of the team” and bold visions are critical for attracting investment. 📊 The focus has shifted from AI algorithms to data access, quality, and longitudinal insights - access to proprietary datasets and solutions that answer a clear market need are key differentiators. 📈 Traditional valuation methods don’t fully capture TechBio’s value; rNPV and ROV, paired with qualitative factors like in vivo POC, offer better frameworks. 🌍 France’s scientific talent is high quality, but scaling globally requires international collaboration and bold, agile strategies. 💭 What are your thoughts on TechBio’s future? #LifeSciences #HealthTech #Innovation

🚀 A Milestone in AI & Protein Design! In a stunning development from EvolutionaryScale, a group of former Meta scientists led by Alex Rives has launched ESM3—a groundbreaking AI protein design model. Dubbed one of the largest AI models globally, ESM3 has the unique ability to "speak the language of proteins." 👨🔬 Their recent work on a new fluorescent protein is not just a demonstration of ESM3's capabilities but also a sneak peek into the myriad innovations imminent in this field. With a whopping $142M seed investment from Lux Capital, the possibilities seem boundless. 💡 How do you think this evolution in AI-driven protein design will impact other sectors? Pharma, biotech, or maybe something unexpected? Celebrating this monumental step—let's engage in what could be the next big revolution in science and technology! #AI #Biotechnology #Innovation #ProteinDesign #ScienceAdvancements #AIProteinDesign #TechTrends

Spotlight Session: ⏱️"Are we ready for AI?" In a dialog at 14.10 pm on Day 2 of Bavaria’s premier biotechnology conference “#BayOConnect”, our 4 experts will discuss the Status Quo of #ArtificialIntelligence in #regulatoryaffairs and how far advanced the approval process for #AI applications is. The interlocutors will be 👉 Prof. Dr. Ariel Dora Stern, Professor for Digital Health, Economics and Policy, Hasso Plattner Institute & Harvard Business School 👉 Friedrich von Bohlen und Halbach of Molecular Health GmbH 👉 Dr. Thomas Wostry, Partner of Ratajczak & Partner Rechtsanwälte Moderated by 👉 Dr. Ulrich Granzer, Owner of Granzer Regulatory Consulting & Services For Prof. Stern it is clear: 📢"We have inherited from the last century a set of institutions for biomedical R&D and regulation that were not designed with today’s most promising new technologies in mind—and AI is one of the settings where this becomes especially salient and where policy updates will be needed."   Her sparring partner Wostry agrees: 📢„As AI becomes a central factor in biotech, upcoming EU regulations and national laws will require a strong AI strategy and competent support to handle new legal challenges.“   If you want to know what the others intervieews will add to the discussion and learn in which direction #regulatory is heading to, then don’t miss out #biotechnology conference “BayOConnect – Forum for Biotech and LifeScience on 📅 2 – 3 July 📍 in #Munich! ⏳ There are only 3 weeks to go until then! Check out the full agenda and register here: ➡️ https://lnkd.in/dGMqmzYS In the afternoon of Day 2 you can also expect these speakers: Prof. Dr. Christian Hinske | Dr. Mark Teese & Dr. Stella Serena Grosso | Dr. Franz MJ Pfister | Nils Krüger | Dr. Henrik Matthies | Dr. Eduardo Beltrán | Dr. Alexander Jarasch #BayOConnect2024 #ArticificialIntelligence #AIapplications #LLM #largeLanguageModels #Bavaria